Anteris Technologies Ltd (avr) Logo

Anteris Technologies Ltd (AVR)

___:___ · AUD

AVR Chart

AVR's Principal Activity is the the manufacturing and sale of proprietary ADAPT regenerative tissue products globally and continued research and development of regenerative medicine. Products under development in the aortic valve repair and replacement programme include DurAVRTM.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) +133.25%
vs ASX 200 (1yr) +119.77%


Market Capitalisation
ASX Rank 1,210 of 2,295
Sector Rank 101 of 177

Key Information

Shares Issued
Sector Healthcare
Similar Companies PAL / CDX / MDC
EPS -$2.58
DPS $0.00
NTA per share -$0.01

Broker Consensus

AVR is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Company Overview

Anteris Technologies Ltd (AVR, formerly Admedus Ltd) is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on investing in and developing next generation technologies with world class partners and acquiring strategic assets to grow product and service offerings.

Incorporation Details

Incorporated bioMD Limited was incorporated in June 1999 in Western Australia. Code changed to Allied Healthcare Group Ltd (AHZ) on 30/06/2011

Corporate Details

Head Office Toowong QLD 4066
Registry Computershare
Auditor HLB Mann Judd Chartered Accountants
Date Listed 24 Mar 2004

Upcoming Calendar (Forecasted)

Date Event
19/08/2021 Report (Interim)
17/02/2022 Report (Prelim)
14/04/2022 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Stephen (Steve) Denaro Company Secretary,Non-Executive Director Oct 2018 Director Bio icon

Mr Stephen (Steve) Denaro

Company Secretary,Non-Executive Director

Mr Denaro has more than 30 years of senior level and Board level experience across publicly-listed companies, serving as Chief Financial Officer, Company Secretary and Director. He brings experience in managing compliance with finance and accounting regulatory requirements. He has had manage investment acquisitions and subsequent funding (domestic and international). Mr Denaro has a interest in start-up companies. He is also a Non-Executive Director and Chair of the Audit & Risk Committee of a not-for-profit company, National Affordable Housing Consortium Limited. He is Chair of the Risk Management Committee.

Dr Wenyi Gu Non-Executive Director Oct 2018 Director Bio icon

Dr Wenyi Gu

Non-Executive Director

Dr Gu currently works as a Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland where he began his postdoctoral work in 2001. Before engaging in nanomedicine, he worked on RNAibased gene therapy for years at Translational Research Institute. Dr Gu's research has been published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. He also held a Peter Doherty Fellowship (2006-2009) and was supported by the National Health and Medical Research Council to work at Harvard Medical School, Harvard University as a visiting fellow. He is a member of the Risk Management Committee.

Mr Wayne Paterson Managing Director,Chief Executive Officer Feb 2016 Director Bio icon

Mr Wayne Paterson

Managing Director,Chief Executive Officer

Mr Paterson has held range of senior positions in multinational pharmaceutical companies. Throughout his career, he has been in charge for building and managing businesses throughout the world, including; mergers, integrations, acquisitions and restructures as President and CEO. From 2005 to 2013 he held senior positions at Merck Kgaa, including President of Europe, Canada and Australia. Prior to this, Mr Paterson was President of markets, President of Japan and Global Head of Cardiovascular Medicine. Between 1999 and 2005, Mr Paterson served at Roche Pharmaceuticals where he was recently Head of Pharmaceuticals in Roche's South Korean operation. He also served as Head of Commercial Operations for Roche China based in Shanghai. He served as Non-Executive Director of Cepheid Inc from April 2015 to November 2016.

Mr John Seaberg Non-Executive Director,Non-Executive Chairman Oct 2014 Director Bio icon

Mr John Seaberg

Non-Executive Director,Non-Executive Chairman

Mr Seaberg has experience in cardiovascular products and markets. From 2008 until its sale to Baxter in 2012, Mr Seaberg served as Chairman of the Board of Synovis Inc. From 2007 until 2014 he was Founder, Chairman and CEO of NeoChord Inc. From 1996 to 2006, Mr Seaberg served at Guidant Corp where he served in range of executive level positions including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In 1991, Mr Seaberg co-founded ACIST Medical and served as its first President and CEO. He was also the founder and CEO of Seaberg Medical. He is a member of the Risk Management Committee.

Matthew Mcdonnell Chief Financial Officer N/A
David St Denis Chief Operating Officer N/A
Martha Engel General Counsel N/A

Director Transactions

AVR directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
07/06/21 Stephen (Steve) Denaro Buy +5,000 $8.009 $40,047 On-market trade
10/12/20 Wayne Paterson Expiry 1,000 $3.80 $3,800 Options expired
10/12/20 John Seaberg Expiry 1,000 $3.80 $3,800 Options expired
20/03/20 Stephen (Steve) Denaro Issued 25,000 $3.50 $87,500 Issue of options
20/03/20 Wayne Paterson Issued 350,000 $3.50 $1,225,000 Issue of options
20/03/20 John Seaberg Issued 60,000 $3.50 $210,000 Issue of options
18/12/18 John Seaberg Issued 700,000 $0.08 $56,000 Rights issue
18/12/18 Yanheng Wu Issued 47,178,461 $0.08 $3,774,278 Rights issue
18/12/18 Lishan Zhang Issued 62,897,248 $0.061 $3,836,732 Rights issue
18/12/18 Yanheng Wu Issued 47,178,461 $0.061 $2,877,886 Rights issue
18/12/18 Lishan Zhang Issued 62,897,248 $0.08 $5,031,781 Rights issue

Director Interests

The current holdings of AVR directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Stephen (Steve) Denaro 07/06/2021 0 5,000 25,000 N/A
Wayne Paterson 31/12/2020 9,167 N/A 403,248 N/A
John Seaberg 31/12/2020 8,858 N/A 67,000 N/A
Wenyi Gu N/A N/A N/A N/A N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Mar 31, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
HSBC Custody Nominees (Australia) Limited A/C 2 650,345 9.90%
National Nominees Limited <Db A/C> 374,479 5.70%
HSBC Custody Nominees (Australia) Limited Gsco Eca 288,924 4.40%
Mercer Street Global Opportunity Fund LLC 280,000 4.26%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 260,807 3.97%
Mr Patrick Chew 176,460 2.69%
Citicorp Nominees Pty Limited 161,115 2.45%
HSBC Custody Nominees (Australia) Limited 150,030 2.28%
CS Fourth Nominees Pty Limited <Hsbc Cust Nom Au Ltd 11 A/C> 129,285 1.97%
Mr Daniel Bernard Clough 89,583 1.36%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> 72,987 1.11%
Amedan Pty Ltd 65,340 0.99%
MDM Leby Hwang 59,000 0.90%
Through2 Investments Pty Ltd <Through2 Super Fund A/C> 48,000 0.73%
Sharepoint Solutions Pty Ltd 46,252 0.70%
J P Morgan Nominees Australia Pty Limited 45,476 0.69%
Mr Joseph John Doyle and Mrs Cheryl Anne Doyle 42,326 0.64%
Sean Barrett Pty Ltd <Super Fund A/C> 41,000 0.62%
Mr Donald Fletcher Cameron and Mrs Anne Cameron <Anne & Don Cameron S/F A/C> 40,000 0.61%
BNP Paribas Nominees Pty Ltd CIBC World Markets Inc <Drp> 30,459 0.46%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 5,322 516 76 72 9 5,995

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Sio Partners LP 31/03/2021 1,311,079 19.96
Mercer Street Global Opportunity Fund, LLC 31/05/2021 383,367 5.52

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
31-05-21 Mercer Street Global Opportunity Fund, LLC 383,367 -- 5.52
20-01-21 Mercer Street Global Opportunity Fund LLC 341,545 -- 5.20

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
20-05-21 Mercer Street Global Opportunity Fund LLC 335,383 5.06 --
13-04-21 Mercer Street Global Opportunity Fund LLC 6,162 5.20 5.06
20-01-21 Sio Partners LP 129,809,772 22.20 19.96

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $4.90 30 June
Page Icon
AVR Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.